Latest & greatest articles for sitagliptin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sitagliptin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on sitagliptin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for sitagliptin

41. Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5) Full Text available with Trip Pro

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5) To compare the efficacy and safety of two doses of once-weekly dulaglutide, a glucagon-like peptide 1 receptor agonist, to sitagliptin in uncontrolled, metformin-treated patients with type 2 diabetes. The primary objective was to compare (for noninferiority and then superiority) dulaglutide 1.5 mg versus sitagliptin in change from baseline in glycosylated hemoglobin (...) A1c (HbA1c) at 52 weeks.This multicenter, adaptive, double-blind, parallel-arm study randomized patients (N = 1,098; mean baseline age 54 years; HbA1c 8.1% [65 mmol/mol]; weight 86.4 kg; diabetes duration 7 years) to dulaglutide 1.5 mg, dulaglutide 0.75 mg, sitagliptin 100 mg, or placebo (placebo-controlled period up to 26 weeks). The treatment period lasted 104 weeks, with 52-week primary end point data presented.The mean HbA1c changes to 52 weeks were (least squares mean ± SE): -1.10 ± 0.06

2014 EvidenceUpdates Controlled trial quality: predicted high

42. Addendum to commission A13-03 (sitagliptin/metformin)

Addendum to commission A13-03 (sitagliptin/metformin) Addendum zum auftrag A13-03 (sitagliptin/metformin) [Addendum to commission A13-03 (sitagliptin/metformin)] Addendum zum auftrag A13-03 (sitagliptin/metformin) [Addendum to commission A13-03 (sitagliptin/metformin)] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Addendum (...) zum auftrag A13-03 (sitagliptin/metformin). [Addendum to commission A13-03 (sitagliptin/metformin)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 187. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Diabetes Mellitus, Type 2; Hypoglycemic Agents; Metformins; Pyrazines; Triazoles Language Published German Country of organisation Germany English summary There is no English language summary available. Address

2014 Health Technology Assessment (HTA) Database.

43. Sitagliptin: benefit assessment according to § 35a Social Code Book V (dossier assessment)

Sitagliptin: benefit assessment according to § 35a Social Code Book V (dossier assessment) Sitagliptin – nutzenbewertung gemäß § 35a SGB V [Sitagliptin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Sitagliptin – nutzenbewertung gemäß § 35a SGB V [Sitagliptin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Sitagliptin – nutzenbewertung gemäß § 35a SGB V. [Sitagliptin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 175. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Diabetes Mellitus, Type 2s; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents

2014 Health Technology Assessment (HTA) Database.

44. Sitagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)

Sitagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment) Sitagliptin/metformin – nutzenbewertung gemäß § 35a SGB V [Sitagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Sitagliptin/metformin – nutzenbewertung gemäß § 35a SGB V [Sitagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Sitagliptin/metformin – nutzenbewertung gemäß § 35a SGB V. [Sitagliptin/metformin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 176. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Diabetes

2014 Health Technology Assessment (HTA) Database.

45. Sitagliptin in the treatment of type 2 diabetes: a meta-analysis

Sitagliptin in the treatment of type 2 diabetes: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

46. Addendum to Commission A13-03 (sitagliptin/metformin)

Addendum to Commission A13-03 (sitagliptin/metformin) 1 Translation of the document “Addendum zum Auftrag A13-03 (Sitagliptin/Metformin)” (Version 1.0; Status: 29 August 2013). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum to Commission A13-03 (sitagliptin/metformin) 1 Addendum IQWiG Reports – Commission No. A13-29 Commission: Version: Status: A13-29 (...) 1.0 29 August 2013 Addendum to Commission A13-03 Version 1.0 (sitagliptin/metformin) 29 August 2013 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic: Addendum to Commission A13-03 (sitagliptin/metformin) Commissioning agency: Federal Joint Committee Commission awarded on: 6 August 2013 Internal Commission No.: A13-29 Address of publisher: Institute for Quality and Efficiency in Health Care Im

2013 Institute for Quality and Efficiency in Healthcare (IQWiG)

47. Sitagliptin/metformin - Benefit assessment according to § 35a Social Code Book V

Sitagliptin/metformin - Benefit assessment according to § 35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment “Sitagliptin/Metformin – Nutzenbewertung gemäß § 35a SGB V” (Version 1.0; Status: 27 June 2013). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A13-03 Sitagliptin/metformin (...) – Benefit assessment according to § 35a Social Code Book V 1 Extract of dossier assessment A13-03 Version 1.0 Sitagliptin/metformin – Benefit assessment acc. to § 35a Social Code Book V 27 June 2013 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sitagliptin/metformin – Benefit assessment according to § 35a Social Code Book V Contracting agency: Federal Joint Committee Commission awarded on: 27

2013 Institute for Quality and Efficiency in Healthcare (IQWiG)

48. Sitagliptin - Benefit assessment according to § 35a Social Code Book V

Sitagliptin - Benefit assessment according to § 35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.8 of the dossier assessment “Sitagliptin – Nutzenbewertung gemäß § 35a SGB V” (Version 1.0; Status: 27 June 2013). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A13-02 Sitagliptin – Benefit assessment according (...) to § 35a Social Code Book V 1 Extract of dossier assessment A13-02 Version 1.0 Sitagliptin – Benefit assessment acc. to § 35a Social Code Book V 27 June 2013 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sitagliptin – Benefit assessment according to § 35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 27 March 2013 Internal Commission No.: A13-02 Address

2013 Institute for Quality and Efficiency in Healthcare (IQWiG)

49. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study (Abstract)

Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study Individuals requiring insulin therapy for type 2 diabetes often require escalation of their regimen to achieve glycaemic control. Optimal management strategies for uncontrolled type 2 diabetes would improve glycaemic control without hypoglycaemia and weight gain. This study compared the efficacy and tolerability of adding sitagliptin, an oral dipeptidyl (...) peptidase-4 inhibitor, and an up to 20% increase in insulin dose in patients with uncontrolled type 2 diabetes on insulin therapy.We conducted a 24-week, randomized, active-competitor, parallel-group study in subjects with uncontrolled type 2 diabetes [haemoglobin A1c (HbA1c) = 7.5-11%] currently using insulin therapy. Subjects were randomly assigned to either the sitagliptin adding (100 mg daily, n = 70) or an insulin-increasing arm (≥ 10% at week 12 and ≥ 10% at week 24, n = 70) while continuing other

2013 EvidenceUpdates Controlled trial quality: uncertain

50. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with Type 2 diabetes experiencing inadequate glycaemic control on metformin and sitaglipti (Abstract)

A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with Type 2 diabetes experiencing inadequate glycaemic control on metformin and sitaglipti To test the hypothesis that glycaemic control achieved when switching sitagliptin to exenatide twice daily plus metformin is non-inferior to adding exenatide twice daily to sitagliptin and metformin.Patients with Type 2 diabetes inadequately (...) controlled with sitagliptin plus metformin were randomly assigned to 20 weeks of treatment with twice-daily exenatide plus placebo and metformin (SWITCH, n = 127) or twice-daily exenatide plus sitagliptin and metformin (ADD, n = 128).Non-inferiority (0.4% margin) of SWITCH to ADD treatment, measured by change in HbA(1c) from baseline to week 20, was not shown {between-treatment difference in least-squares mean [95% CI 3 mmol/mol (0.30%)] [0.8-5.8 (0.07-0.53)]}. A greater reduction (P = 0.012) in HbA(1c

2012 EvidenceUpdates Controlled trial quality: uncertain

51. Sitagliptin (Januvia®) 25 and 50 mg tablets

Sitagliptin (Januvia®) 25 and 50 mg tablets Sitagliptin (Januvia®) 25 and 50 mg tablets Sitagliptin (Januvia®) 25 and 50 mg tablets All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Sitagliptin (Januvia®) 25 and 50 mg tablets. Penarth: All Wales Therapeutics and Toxicology (...) Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2912. 2012 Authors' conclusions Sitagliptin (Januvia®) 25 and 50 mg tablets are recommended as an option for use within NHS Wales for the improvement of glycaemic control in type 2 diabetes mellitus patients with moderate renal impairment (CrCl = 30 to < 50 ml/min), severe renal impairment (CrCl < 30 ml/min) or with end-stage renal disease (ESRD) requiring haemodialysis

2012 Health Technology Assessment (HTA) Database.

52. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. (Abstract)

Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. In people with type 2 diabetes, a dipeptidyl peptidase-4 (DPP-4) inhibitor is one choice as second-line treatment after metformin, with basal insulin recommended as an alternative. We aimed to compare the efficacy, tolerability, and safety of insulin glargine and sitagliptin, a DPP-4 inhibitor, in patients whose disease (...) mmol/L) or sitagliptin (oral dose of 100 mg daily). Randomisation (via a central interactive voice response system) was by random sequence generation and was stratified by centre. Patients and investigators were not masked to treatment assignment. The primary outcome was change in HbA(1c) from baseline to study end. Efficacy analysis included all randomly assigned participants who had received at least one dose of study drug and had at least one on-treatment assessment of any primary or secondary

2012 Lancet Controlled trial quality: predicted high

53. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study Full Text available with Trip Pro

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study To test the safety and efficacy of exenatide once weekly (EQW) compared with metformin (MET), pioglitazone (PIO), and sitagliptin (SITA) over 26 weeks, in suboptimally treated (diet and exercise) drug-naive patients with type 2 diabetes.Patients were randomized to subcutaneous (SC) EQW 2.0 mg

2012 EvidenceUpdates Controlled trial quality: uncertain

54. Janumet XR (sitagliptin/metformin hydrochloride extended release)

Janumet XR (sitagliptin/metformin hydrochloride extended release) Drug Approval Package: JANUMET XR (sitagliptin/metformin hydrochloride) NDA #202270 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - JANUMET XR (sitagliptin/metformin hydrochloride extended release) fixed-dose combination tablets, 100 mg/1000 mg, 50 mg/500 mg, and 50 mg/1000 mg Company: Merck Sharp & Dohme Corp. Application No.: 202270 Approval Date: 02/02/2012 Persons with disabilities

2012 FDA - Drug Approval Package

55. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial Full Text available with Trip Pro

The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial To compare the incidence of symptomatic hypoglycaemia in fasting Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan.Patients with type 2 diabetes (age ≥ 18 years) who were treated with a stable dose of a sulphonylurea with or without metformin for at least 3 months prior to screening, who had an HbA(1c (...) ) < 10% and who expressed their intention to daytime fast during Ramadan were eligible for this open-label study. Patients were randomised in a 1 : 1 ratio to either switch to sitagliptin 100 mg qd or to remain on their prestudy sulphonylurea. Patients completed daily diary cards to document information on hypoglycaemic symptoms and complications. The primary end-point was the overall incidence of symptomatic hypoglycaemia recorded during Ramadan.Of the 1066 patients randomised, 1021 (n = 507

2012 EvidenceUpdates Controlled trial quality: uncertain

56. Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naive patients with type 2 diabetes (Abstract)

Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naive patients with type 2 diabetes The efficacy and safety of sitagliptin (SITA) monotherapy and SITA/metformin (MET) vs. pioglitazone (PIO) were assessed in patients with type 2 diabetes and moderate-to-severe hyperglycaemia (A1C = 7.5-12.0%).In an initial 12-week phase (Phase A), 492 patients were randomised 1 : 1 in a double-blind fashion to SITA (100 mg qd) or PIO (15 mg

2011 EvidenceUpdates Controlled trial quality: uncertain

57. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of beta-cell function in patients with type 2 diabetes (Abstract)

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of beta-cell function in patients with type 2 diabetes To assess the safety and efficacy of initial combination therapy with sitagliptin and pioglitazone compared with pioglitazone monotherapy in drug-naïve patients with type 2 diabetes.A total of 520 patients were randomised to initial combination therapy with sitagliptin 100 mg q.d. and pioglitazone 30 (...) mg q.d. or pioglitazone 30 mg q.d. monotherapy for 24 weeks.Initial combination therapy with sitagliptin and pioglitazone led to a mean reduction from baseline in A1C of -2.4% compared with -1.5% for pioglitazone monotherapy (p<0.001). Mean reductions from baseline were greater in patients with a baseline A1C≥10% (-3.0% with combination therapy vs. -2.1% with pioglitazone monotherapy) compared with patients with a baseline A1C<10% (-2.0% with combination therapy vs. -1.1% with pioglitazone

2011 EvidenceUpdates Controlled trial quality: uncertain

58. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis

Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

59. Sitagliptin phosphate monohydrate / metformin hydrochloride - type 2 diabetes

Sitagliptin phosphate monohydrate / metformin hydrochloride - type 2 diabetes Common Drug Review CEDAC Meeting – March 24, 2010; CEDAC Reconsideration – June 16, 2010 Notice of CEDAC Final Recommendation – June 23, 2010 Page 1 of 3 © 2010 CADTH CEDAC FINAL RECOMMENDATION SITAGLIPTIN / METFORMIN (Janumet – Merck Frosst Canada Ltd.) Indication: Type 2 Diabetes Mellitus Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that sitagliptin / metformin (Janumet) be listed (...) for use in patients for whom insulin is not an option and who are already stabilized on therapy with metformin, a sulfonylurea and sitagliptin, to replace the individual components of sitagliptin and metformin in these patients. Reason for the Recommendation: The cost of Janumet is similar to or less than the cost of sitagliptin and metformin administered separately. The confidential price of Janumet was used to make the CEDAC recommendation and the manufacturer requested this information be kept

2010 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

60. Sitagliptin phosphate - type 2 diabetes

Sitagliptin phosphate - type 2 diabetes Common Drug Review CEDAC Meeting – March 24, 2010; CEDAC Reconsideration – June 16, 2010 Notice of CEDAC Final Recommendation – June 23, 2010 Page 1 of 6 © 2010 CADTH CEDAC FINAL RECOMMENDATION SITAGLIPTIN RESUBMISSION (Januvia – Merck Frosst Canada Ltd.) Indication: Type 2 Diabetes Mellitus This recommendation supersedes the CEDAC recommendation for this drug and indication dated June 18, 2008. Recommendation: The Canadian Expert Drug Advisory Committee (...) (CEDAC) recommends that sitagliptin be listed as a third drug added on to metformin and a sulfonylurea for patients with inadequate glycemic control on metformin and a sulfonylurea and for whom insulin is not an option. Reasons for the Recommendation: 1. In one double-blind randomized controlled trial, patients with inadequate glycemic control on a sulfonylurea plus metformin who had sitagliptin added on to therapy, had statistically significantly greater reductions in haemoglobin A1c, fasting plasma

2010 Canadian Agency for Drugs and Technologies in Health - Common Drug Review